METAP
16.12.2021 07:26:05 CET | Business Wire | Press release
Gensokishi Online has announced the release of its official website "Gensokishi Online -META WORLD- " in Dec. 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215006137/en/
This project is a new version of "Gensokishi Online", which won the "Game of the year, Gold Award" in 2012 in Taiwan and has been played by a total of 8 million users. Gensokishi aims to build a new fantasy world economy with blockchain technology, incorporating NFT and GameFi elements into a 3D MMO world metaverse.
"Gensokishi Online", a Japanese 3D MMO title licensed from "Elemental Knights Online", has been trusted and proven for more than 13 years on various apps, Nintendo Switch and PlayStation4.
In the world created by WEB3.0, Metaverse, and GameFi, Gensokishi will realize the three features of "Free to Play", "Play to Earn", and "UGC to Earn".
Anyone can create an account for free and buy and sell the NFT items and tokens they acquire.
In the future, Genoskishi plans to offer "UGC (User Generated Contents)," which will allow users and companies to create and sell NFT items, as well as the right to freely create land, place objects, natural environments, characters, and monsters in the metaverse.
Gensokishi operates on top of Polygon (MATIC), better known as an Ethereum based protocol that allows players to get the benefits of high transaction capabilities and low costs.
Furthermore, this initiative also includes participation from key personalities in the video game industry.
The MV token will be on Uniswap on Dec. 23, 2021. For more information, please see the white paper .
About the Campaign
Various campaigns are being held to celebrate the announcement of Gensokishi Online.
Community Registration Campaign
A campaign is currently being held to distribute "Limited Equipment NFT" to all those who join the community by Dec. 27, 2021.
Whitelist
Starting Dec. 7, Gensokishi is running a $10,000 Whitelist Campaign , and if you enter by Dec. 19, you will be entitled to purchase up to $100 worth of token at private sale prices.
Official Community
Twitter
Telegram
Discord
Service Outline
Description: Gensokishi Online -META WORLD-
Languages: English, Chinese, Japanese
System Requirements: PC, Android, iOS
Source : Taiwan Gensokishi Online Project Metap.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006137/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 12:45:00 CET | Press release
A year after its Milan debut, TVS Motor returns with a rapidly expanding European footprint and Italian sales up 110%Peyman Kargar to lead TVS Motor’s next phase of global growth as the company expands European footprint TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its deal
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom